Moderna Inc. (MRNA) shares surged approximately 9% on Friday, extending a rally that has pushed the stock roughly 40% higher over the past month and significantly outpaced the broader market. The gains followed the company's Science Day presentation, where management outlined a strategic expansion beyond its COVID-19 vaccine franchise into oncology, autoimmune diseases, and next-generation mRNA therapies.
In Vivo CAR-T Program Drives Investor Enthusiasm
The most closely watched announcement was Moderna's first in vivo CAR-T program, designated mRNA-6007. The company plans to initiate clinical development in 2027, initially targeting B-cell-mediated autoimmune diseases such as systemic lupus erythematosus. In vivo CAR-T therapies genetically modify patients' T-cells directly inside the body, an approach that could prove more efficient and less costly than traditional ex vivo methods, which require cell extraction, laboratory modification, and reinfusion.
This technology has attracted significant industry interest. Eli Lilly (LLY) entered the space earlier this year through its acquisition of Orna Therapeutics, gaining access to its in vivo CAR-T platform. Moderna's entry further validates the category, potentially benefiting the entire sector.
Pipeline Expansion Beyond COVID Vaccines
Moderna's Science Day presentation provided investors with a detailed look at its long-term development strategy, organized into three distinct horizons. The first horizon focuses on existing commercial products and late-stage programs. Jefferies analyst Andrew Tsai estimates that Moderna could market more than seven products across respiratory, oncology, and rare disease indications within the next two years, a significant expansion from its current portfolio of three vaccines.
Among the notable pipeline updates was mRNA-4194, the company's first cancer prevention program targeting patients with Lynch syndrome. Additionally, Moderna discussed progress on mRNA-1195, an Epstein-Barr virus therapeutic vaccine being developed for multiple sclerosis, with early data expected later in 2026.
Investors also welcomed progress in Moderna's influenza franchise. The company's flu vaccine candidate, mRNA-1010, recently received a unanimous 9-0 vote from an FDA advisory committee for adults aged 50 and older, ahead of a regulatory decision scheduled for August 5, 2026. For more on this catalyst, see Moderna Surges 9% on FDA Panel Nod for Flu Shot, Pipeline Expansion into Oncology.
Analyst Reactions and Price Targets
Wall Street analysts responded positively to Moderna's latest updates. Piper Sandler raised its price target on Moderna shares to $77 from $69 while maintaining an Overweight rating, citing the progress showcased during Science Day. Jefferies analyst Andrew Tsai expressed optimism about the company's early-stage oncology programs and emerging treatment modalities, noting they "can meaningfully diversify the mRNA pipeline." However, Tsai views upcoming Phase III melanoma data as an even larger near-term catalyst, calling it "a major event" for the stock. He maintained a Hold rating while raising his price target to $53 from $45.
For context on broader market movements, see European Stocks Hit New Highs: STOXX 600, DAX Record Weekly Gains on Rate Optimism.
Key Risks and Considerations
While investor sentiment is bullish, key risks remain. In vivo CAR-T safety or efficacy could disappoint in early trials, potentially slowing or derailing the program. Additionally, the broader in vivo CAR-T field faces clinical performance uncertainty, which could reduce investor appetite for the platform. Moderna's transition from a COVID vaccine story to a diversified platform company is still in its early stages, and near-term revenue will continue to depend on vaccine sales.
For a look at another company benefiting from AI-driven optimism, see Intel Stock Jumps 7% as AI Infrastructure Optimism and Foundry Progress Drive Rally.
This article is for informational purposes only and does not constitute financial advice.
